Daniel Lundell
Overview
Explore the profile of Daniel Lundell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tong L, Kim S, Chen L, Kosinski A, Shankar B, Girijavallabhan V, et al.
Bioorg Med Chem Lett
. 2017 Jul;
27(16):3704-3708.
PMID: 28711352
Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors led to fused bi-heteroaryl hydantoin series that demonstrate sub-nanomolar potency (Ki) as well as excellent activity in human whole blood...
2.
Tong L, Kim S, Rosner K, Yu W, Shankar B, Chen L, et al.
Bioorg Med Chem Lett
. 2017 Jun;
27(14):3037-3042.
PMID: 28558971
We have identified a series of hydantoin-derived TNF-a converting enzyme (TACE) inhibitors containing a pendant fused bi-heteroaryl group, which demonstrate sub-nanomolar potency (Ki), excellent activity in human whole blood assay,...
3.
Hanisak J, Seganish W, McElroy W, Tang H, Zhang R, Tsui H, et al.
Bioorg Med Chem Lett
. 2016 Aug;
26(17):4250-5.
PMID: 27476420
IRAK4 has been identified as potential therapeutic target for inflammatory and autoimmune diseases. Herein we report the identification and initial SAR studies of a new class of pyrazole containing IRAK4...
4.
Seganish W, Fischmann T, Sherborne B, Matasi J, Lavey B, McElroy W, et al.
ACS Med Chem Lett
. 2015 Aug;
6(8):942-7.
PMID: 26288698
We report the identification and synthesis of a series of aminopyrimidin-4-one IRAK4 inhibitors. Through high throughput screening, an aminopyrimidine hit was identified and modified via structure enabled design to generate...
5.
Seganish W, McElroy W, Herr R, Brumfield S, Greenlee W, Harding J, et al.
Bioorg Med Chem Lett
. 2015 Jun;
25(16):3203-7.
PMID: 26115573
IRAK4 plays a key role in TLR/IL-1 signaling. Previous efforts identified a series of aminopyrimidine IRAK4 inhibitors that possess good potency, but modest kinase selectivity. Exploration of substituents at the...
6.
McElroy W, Tan Z, Ho G, Paliwal S, Li G, Seganish W, et al.
ACS Med Chem Lett
. 2015 Jun;
6(6):677-82.
PMID: 26101573
IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified...
7.
Xiao D, Zhu X, Sofolarides M, Degrado S, Shao N, Rao A, et al.
Bioorg Med Chem Lett
. 2014 Jun;
24(15):3609-13.
PMID: 24913714
A unified strategy was conceived and implemented to deliver conformationally constrained anilides based on their preferred cis-amide conformers. The imidazole/triazole mimicing amide bonds were designed, building upon an earlier discovery...
8.
Qin J, Dhondi P, Huang X, Aslanian R, Fossetta J, Tian F, et al.
ACS Med Chem Lett
. 2014 Jun;
3(2):100-5.
PMID: 24900435
Inhibition of MK2 has been shown to offer advantages over that of p38 MAPK in the development of cures for inflammatory diseases such as arthritis. P38 MAPK knockout in mice...
9.
Ting P, Lee J, Kuang R, Cao J, Gu D, Huang Y, et al.
Bioorg Med Chem Lett
. 2013 Sep;
23(20):5528-32.
PMID: 24018187
The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and...
10.
Xiao D, Palani A, Huang X, Sofolarides M, Zhou W, Chen X, et al.
Bioorg Med Chem Lett
. 2013 Apr;
23(11):3262-6.
PMID: 23602398
Conformation restriction of linear N-alkylanilide MK2 inhibitors to their E-conformer was developed. This strategy enabled rapid advance in identifying a series of potent non-ATP competitive inhibitors that exhibited cell based...